CA2664841A1 - Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma - Google Patents

Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma Download PDF

Info

Publication number
CA2664841A1
CA2664841A1 CA002664841A CA2664841A CA2664841A1 CA 2664841 A1 CA2664841 A1 CA 2664841A1 CA 002664841 A CA002664841 A CA 002664841A CA 2664841 A CA2664841 A CA 2664841A CA 2664841 A1 CA2664841 A1 CA 2664841A1
Authority
CA
Canada
Prior art keywords
pda
enolase
alpha
antibodies
enoa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002664841A
Other languages
English (en)
French (fr)
Inventor
Francesco Novelli
Barbara Tomaino
Paola Cappello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribovax Biotechnologies SA
Bioline Diagnostici SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2664841A1 publication Critical patent/CA2664841A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G01N33/57525—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002664841A 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma Abandoned CA2664841A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06121552.1 2006-09-29
EP06121552 2006-09-29
EP06126726.6 2006-12-20
EP06126726 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (1)

Publication Number Publication Date
CA2664841A1 true CA2664841A1 (en) 2008-04-03

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002664841A Abandoned CA2664841A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Country Status (18)

Country Link
US (1) US8071721B2 (enExample)
EP (1) EP2069395B1 (enExample)
JP (1) JP2010505104A (enExample)
KR (1) KR20090094227A (enExample)
CN (1) CN101578295B (enExample)
AT (1) ATE542831T1 (enExample)
AU (1) AU2007301966B2 (enExample)
BR (1) BRPI0717282A2 (enExample)
CA (1) CA2664841A1 (enExample)
DK (1) DK2069395T3 (enExample)
EA (1) EA016731B1 (enExample)
ES (1) ES2381304T3 (enExample)
IL (2) IL197868A (enExample)
NO (1) NO20091662L (enExample)
NZ (1) NZ576409A (enExample)
PL (1) PL2069395T3 (enExample)
PT (1) PT2069395E (enExample)
WO (1) WO2008037792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500964A (ja) * 2008-05-09 2012-01-12 デューク ユニバーシティ 癌の検出と治療における自己抗体
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
RU2656153C1 (ru) * 2013-12-20 2018-05-31 Девелопмент Сентер Фор Байотекнолоджи Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
MX2016009102A (es) 2014-01-13 2016-09-09 Berg Llc Composiciones de enolasa 1 (eno1) y sus usos.
CN115786317A (zh) * 2022-12-12 2023-03-14 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Also Published As

Publication number Publication date
WO2008037792A1 (en) 2008-04-03
PL2069395T3 (pl) 2012-06-29
IL197868A0 (en) 2011-08-01
IL197868A (en) 2013-03-24
AU2007301966B2 (en) 2013-02-21
EA200970332A1 (ru) 2009-10-30
DK2069395T3 (da) 2012-05-14
EP2069395A1 (en) 2009-06-17
EP2069395B1 (en) 2012-01-25
PT2069395E (pt) 2012-04-27
NO20091662L (no) 2009-06-29
ES2381304T3 (es) 2012-05-25
IL218442A0 (en) 2012-04-30
KR20090094227A (ko) 2009-09-04
ATE542831T1 (de) 2012-02-15
JP2010505104A (ja) 2010-02-18
CN101578295B (zh) 2013-02-27
BRPI0717282A2 (pt) 2013-10-15
US20100028907A1 (en) 2010-02-04
EA016731B1 (ru) 2012-07-30
US8071721B2 (en) 2011-12-06
CN101578295A (zh) 2009-11-11
AU2007301966A1 (en) 2008-04-03
NZ576409A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
ES2321197T3 (es) Fosforilacion de proteinas en rutas de señalizacion de c-src.
US8071721B2 (en) Antigens and antibodies associated to pancreatic ductal adenocarcinoma
Buanne et al. Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells
Wang et al. An autoantigen atlas from human lung HFL1 cells offers clues to neurological and diverse autoimmune manifestations of COVID-19
US10809263B2 (en) Antigenic composition for detecting auto-antibody with specific response to exosomal protein EIF3A, and method for diagnosing liver cancer using antigenic composition
JP2013061321A (ja) 組織因子経路阻害因子２（ｔｆｐｉ２）測定による卵巣明細胞腺癌の検査方法および検査薬
Zhang et al. Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA
EP3042203B1 (en) Biomarkers for cholangiocellular carcinoma (ccc)
WO2010071788A1 (en) Pancreatic cancer markers and uses thereof
Bonnez et al. Unraveling antibody-induced structural dynamics in the ADAMTS13 CUB1-2 domains via HDX-MS
CA2909474C (en) New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation
EP2535715B1 (en) METHOD FOR MEASURING IMMUNITY OF COMPLEX OF Ku86 AND AUTOANTIBODY THEREOF, KIT USED THEREFOR, AND METHOD FOR DETERMINING CANCER USING SAME
Thakar et al. SUMOylation of the hepatoma‐derived growth factor negatively influences its binding to chromatin
Ye et al. Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics
Zurawel et al. Proteomic profiling of the mesenteric lymph after hemorrhagic shock: differential gel electrophoresis and mass spectrometry analysis
EP4526341A1 (en) High affinity antibodies specifically binding to alpha-1,6-core-fucosylated alpha-fetoprotein
KR20120094711A (ko) 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
Saar-Kovrov et al. Protein carbamylation in atherosclerotic plaques correlates with uremia and disease progression, localizing predominantly to foam cells
Cho et al. Glypican 3 binds to GLUT1 and decreases glucose transport activity in hepatocellular carcinoma cells
WO2011149402A2 (en) Prostate cancer biomarkers
Miranda et al. Heterologous expression of Homo sapiens alpha-folate receptors in E. coli by fusion with a trigger factor for enhanced solubilization
Tian et al. USP13 Regulates the Breast Tumor Proliferation and Migration through the Stabilization of PDCD4 Protein
EP3346271A1 (en) Methods and kits for detecting cancer
Semaan Proteomics of putative protein biomarkers in human breast cancer tissues
Castillo Mass Spectrometry-Based Approaches for Targeted Quantitative Proteomics in Biomarker Development

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140930